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Abstract 
Objectives: Public health campaigns encouraging early help-seeking have increased rates 
of Mild Cognitive Impairment (MCI) diagnosis in Western countries, but we know little about 
how to treat or prognosticate dementia outcomes in persons with MCI.  
Method: We searched electronic databases and references for longitudinal studies reporting 
potentially modifiable risk factors for incident dementia after MCI. Two authors independently 
evaluated study quality using a checklist. We meta-analysed findings from three or more 
studies. 
Results: We identified 76 eligible papers. Diabetes and prediabetes increased risk of 
conversion from amnestic MCI (aMCI) to Alzheimer’s Dementia (AD); risk in treated versus 
untreated diabetes was lower in one study. Diabetes was also associated with increased risk 
of conversion from any type or non-amnestic MCI to all cause dementia. Metabolic 
syndrome and pre-diabetes predicted all cause dementia in people with aMCI and any type 
MCI respectively. Mediterranean diet decreased risk of conversion from aMCI to AD. 
Presence of neuropsychiatric symptoms or lower serum folate levels predicted conversion 
from any type MCI to all cause dementia, but less formal education did not. Depressive 
symptoms predicted conversion from any type MCI to dementia in epidemiological, but not 
clinical studies. 
Conclusions: Diabetes increased the risk of conversion to dementia. Other prognostic 
factors that are potentially manageable are pre-diabetes and the metabolic syndrome, 
neuropsychiatric symptoms and low dietary folate. Dietary interventions and interventions to 
reduce neuropsychiatric symptoms including depression, which increase conversion risk to 
dementia, may decrease incident dementia.  
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Introduction 
Mild cognitive impairment (MCI) is a state between normal aging and dementia. It is defined 
as objective cognitive impairment for age, with concern about cognitive symptoms (whether 
concern of the patient, carer or clinician) in a person with essentially normal functional 
activities, who does not have dementia1;2. It affects 19% of people aged 65 and over3. 
Around 46% of people with MCI develop dementia within 3 years compared to 3% of the age 
matched population4. People with MCI are clinically and neuropathologically heterogeneous. 
A subgroup of people with MCI who have progressive symptoms and particular impairment 
of episodic memory, termed amnestic MCI (aMCI)1 or MCI due to Alzheimer’s disease2, are 
more likely to progress to AD.  
 
Public health campaigns encouraging early help-seeking have resulted in increasing rates of 
MCI diagnosis in Western countries, but we know little about how to treat or prognosticate 
outcomes. Neither the U.S. Food and Drug Administration (FDA) nor the UK National 
Institute for Health and Clinical Excellence (NICE) recommend drug treatments, although 
follow-up is advised, to ensure dementia is diagnosed and care planned early5. People 
presenting with MCI want information about their risk of developing dementia and how to 
reduce it.  
In our recent systematic review of 41 Randomised Controlled Trials (RCT) in MCI, we found 
no consistent evidence for the efficacy of any intervention to reduce incident dementia, or 
cognitive decline6. Theoretically, neuroprotection, treating vascular risk factors, or increasing 
cognitive reserve, could be targeted at people with MCI who have a high risk of dementia. 
We concluded that cholinesterase inhibitors and rofecoxib are ineffective in preventing 
dementia. Cognition improved in single trials of: a heterogeneous psychological group 
intervention over 6 months; piribedil, a dopamine agonist over 3 months; and donepezil over 
48 weeks. Nicotine improved attention over 6 months. There was equivocal evidence that 
Huannao Yicong, a Chinese herbal preparation improved cognition and social functioning.  
In the absence of consistent RCT evidence of effective interventions, observational cohort 
studies evaluating predictors of dementia in MCI are the best available evidence. Systematic 
reviews have reported that in mixed older populations, mostly without MCI, incident AD has 
been predicted by higher homocysteine levels, lower educational attainment, and decreased 
physical activity14. Conflicting results have been reported for the association between 
dementia and other putative risk factors (smoking) and protective factors (mild-to-moderate 
alcohol consumption, dietary antioxidants, Mediterranean diet, and living with others)16. 
Neuropsychiatric symptoms predict MCI in cognitively normal populations15. These factors 
are possibly relevant for people with MCI, many of whom have some pathology of a 
dementing condition but have yet to develop clinical dementia. 
Objectives 
To synthesise evidence from longitudinal, observational studies regarding modifiable risk 
factors that predict conversion to dementia in people with MCI.  
 
Methods 
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Search strategy and selection criteria 
We searched PubMed (1946-) and Web of Knowledge (1900-) through 22 May 2013 
(updated 5 June 2014), using the terms: mild cognitive, cognitive impairment, benign 
senescent forgetfulness, age associated cognitive decline, age-associated memory 
impairment, age-related cognitive decline or mild neurocognitive disorder together with 
dementia AND dementia incidence, incident dementia, incidence of dementia, prospective, 
cohort or longitudinal. No limits were applied for language or time published. We searched 
references of included papers. We excluded meeting abstracts. 
 
We included longitudinal studies reporting potentially modifiable risk factors for incident 
dementia in people with MCI. We defined MCI as cognitive impairment identified from 
objective neuropsychological tests, in the absence of dementia or significant functional 
impairment. We included studies whether or not they specified the presence of subjective 
memory impairment. We report study results for people with aMCI (requiring presence of 
objective memory impairment), non-aMCI, any MCI type (requiring objective impairment in 
any cognitive domain), and also predictors of all cause dementia, Alzheimer’s dementia, or 
other dementias separately. We divided studies into epidemiological studies, which identified 
cases of MCI from the general population or in comprehensive surveys, and clinical studies, 
in which people already diagnosed with MCI in clinical settings were recruited, as the rates 
of conversion to dementia may differ. We defined a modifiable risk factor as one potentially 
changeable through lifestyle or existing medical treatment.  
Quality assessment 
CC extracted study characteristics and findings (see Tables for data extracted). To assess 
risk of bias, two authors (CC, AS) independently evaluated study quality against criteria 
devised by the authors, derived from published checklists17: 
1.  A defined representative sample of participants assembled at a common point in 
the course of their disease, or recruited to be representative of the general older 
population, with a response rate of at least 60% of eligible potential participants. 
2. Participant follow-up for at least a year, with at least 70% followed up. 
3. Criteria for diagnosing MCI and dementia were objective or applied in a ‘masked’ 
fashion. 
Disagreements were resolved by consensus. We described studies meeting all these criteria 
as higher quality studies. We assigned grades of evidence in support of conclusions: “grade 
1 evidence” was consistent evidence from higher quality studies; “grade 2 evidence” was 
from a single higher quality study, or consistent evidence from other studies; and 
“inconsistent evidence” was troublingly inconsistent evidence.  
Data analysis  
We conducted meta-analyses (random effects models) for findings where data from three or 
more studies could be combined. We calculated unadjusted pooled odds ratios for 
dichotomous outcomes and standardised effect sizes from means and standard deviations 
for continuous outcomes using Statsdirect version 2.8.0.  
Results 
Search results 
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Figure 1 shows our search strategy results. We included 76 papers reporting 62 studies. 
Validity 
We report characteristics and results from the 9 higher quality studies, all epidemiological (in 
14 papers) and 8 other epidemiological studies in Tables 1 and 2; and 45 clinical studies 
(described in 58 papers) in Table 3. Thirty of the 62 studies are included in meta-analyses; 
other results are reported qualitatively. 
Risk factors for cerebrovascular disease 
Diabetes: Ten studies examined diabetes, including insulin and non-insulin dependent 
diabetes, with diagnoses from medical records or clinical examination and blood glucose 
measurement. The unadjusted pooled odds ratio (OR) for conversion to dementia in people 
with and without diabetes was 1.65 (95% CI 1.12 to 2.43) for the 7/10 studies (Figure 2a) for 
which data was available, with the three excluded studies also showing this trend. Studies in 
aMCI populations (reporting conversion to AD) and any type MCI populations (reporting 
conversion to all cause dementia) reported similar findings.  
In large, higher quality epidemiological18 and clinical19 studies, people with aMCI and 
diabetes were more likely to progress to AD than those without diabetes, while in a third, 
small study a similar trend was not statistically significant20. The higher quality, 
epidemiological study, reported those with treated diabetes were less likely to convert to AD 
than those with untreated diabetes, suggesting this risk may be modifiable18. In a further 
clinical study, people with prediabetes or diabetes (fasting glucose >100 mg/dL) were more 
likely to progress from any type MCI to AD21. 
In the only study to explore the impact of diabetes on risk of progression from non-amnestic 
MCI to any cause dementia, a higher quality epidemiological study, diabetes or prediabetes 
was a significant predictor22. Three small and likely underpowered epidemiological studies 
reported the impact of diabetes on the risk of progressing from aMCI to any cause dementia 
(of whom most had AD). One found that diabetes was a risk factor for progression23, a 
second a similar trend22 and the third no such relationship24.  
Four studies investigated the impact of diabetes on progression from any MCI subtype to all 
cause dementia. One higher quality epidemiological study found that diabetes was a 
significant predictor, and prediabetes a stronger predictor AD22. In a smaller higher quality 
epidemiological study there was a trend towards diabetes being a significant predictor of 
conversion to any cause dementia (HR 1.35, p=0.1)25, while in a third epidemiological study 
diabetes predicted dementia26. In a small clinical study in which only four people with 
diabetes developed dementia, diabetes did not predict dementia27.  
Hypertension: Eleven studies investigated current hypertension, recorded from medical 
records or physical examination and medication review. The unadjusted pooled OR was 
1.19 (95% CI 0.81 to 1.73) for the 7/11 studies (Figure 2b), with three of the studies that 
could not be included also showing no significant relationship19;25;28 and a fourth that 
hypertension decreased conversion risk29.  
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We found consistent evidence that in studies of people with any type MCI, hypertension 
predicted all cause dementia. Pooled OR for 4/6 of these studies for which unadjusted OR 
was calculated (Figure 2b) was 1.05 (0.60 to 1.85). Two of four epidemiological studies 
investigating this, including the only higher quality study, found no significant 
relationship25;26;30. Another epidemiological study found that hypertension decreased the risk 
of transition to dementia from any type MCI29, while in the fourth study hypertension 
significantly increased this risk on unadjusted analysis, but not when controlled for factors 
including stroke26. Two clinical studies also found no such relationship27;31 . 
For conversion from aMCI to AD, the evidence was less consistent. The only large, higher 
quality epidemiological study to investigate conversion from aMCI to AD found that 
hypertension did significantly predict this, while treated hypertension had lower risk than no 
antihypertensive treatment18. In three clinical studies investigating this however, 
hypertension was not a significant predictor19;20;28. In a small epidemiological study 
investigating predictors of conversion from aMCI to dementia, hypertension was also not a 
significant predictor24.  
In addition, clinical studies reported that for each 10mmHg decrease in systolic blood 
pressure or diastolic blood pressure there was a significant reduction in risk of conversion 
from any type MCI to dementia27; and that systolic or diastolic blood pressure readings did 
not predict conversion from aMCI to AD32 and treatment with a diuretic was associated with 
a lower risk of conversion from any type MCI to AD, compared with no antihypertensive 
treatment33. 
Hypercholesterolemia: One higher quality epidemiological study reported that 
hypercholesterolemia predicted conversion from aMCI to AD, and that those with treated 
versus untreated hypercholesterolemia were less likely to develop AD18, while in a clinical 
study hypercholesterolaemia did not predict conversion from aMCI to AD20. In two 
epidemiological studies, one of which was higher quality25;26, hypercholesterolemia did not 
predict dementia in people with all type MCI [pooled unadjusted OR from 3 studies18;20;26 
0.92 (0.50 to 1.68)]. 
A clinical study found that people with all type MCI who had cholesterol levels in the highest 
quartile (>250mg/dL) were less likely to develop dementia than those with lower levels27, 
although serum HDL and LDL levels did not predict conversion in the same study34. Two 
other clinical studies found that serum LDL35, HDL and cholesterol levels24 did not predict 
conversion from aMCI to dementia. 
Smoking: The unadjusted pooled OR for a history of ever smoking was 0.45 (95% CI 0.24 to 
0.84) from three studies23;24;27, but was not significant in any study after controlling for age, 
indicating this was probably due to the competing risk of mortality. An epidemiological study 
reported that the mean time to all cause dementia was shorter in people with all type MCI 
who currently smoked than in those who did not36; but those who had never smoked were at 
greater risk than those who had smoked for 20 pack years or more36;37. This conflicting 
finding likely also resulted from competing mortality: smokers developed dementia sooner, 
but were more likely to die before developing dementia. Conversion from all type MCI to any 
cause dementia was not predicted by smoking status in two epidemiological studies25;26, one 
higher quality25, and a clinical study after adjusting for age, gender and education27. There 
was no significant association between risk of AD in people with aMCI and smoking status in 
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a higher quality epidemiological18 or a clinical study38. Ever smoking did not predict 
conversion from aMCI to any dementia in two further studies23;24.  
Alcohol: Three higher quality epidemiological studies investigated moderate alcohol 
consumption. In the first, drinking alcohol, specifically wine moderately (<1 drink per day) as 
opposed to abstaining, predicted a lower risk of all cause dementia in people with aMCI39. 
Other highest quality studies found that daily, compared to less frequent drinking did not 
predict AD in people with aMCI18, and that compared to abstinence, neither drinking within 
normal limits, nor harmful, risky or addictive drinking (classified using World Health 
organisation guidelines) predicted risk of all cause dementia in people with any type MCI25. 
While none of these studies specifically excluded heavy drinkers, few participants drank 
more than one drink a day in the two studies that reported overall alcohol consumption18;39.  
Two studies, one epidemiological and one clinical, reported whether drinking any alcohol 
currently, as opposed to abstaining predicted conversion from any type MCI to dementia26 
and from aMCI to AD38. Neither study found this relationship was significant. Finally, two 
clinical studies compared people with a lifetime history of heavy drinking to those without. 
One found that those with a history of heavy drinking were more, and moderate drinkers less 
likely than abstainers to convert from any type MCI to dementia40. In the second, small study 
that was probably underpowered, there was a non-significant trend (HR 2.6, p=0.1) towards 
people with aMCI who had a history of heavy drinking being more likely to develop 
dementia23. 
Metabolic syndrome (3+ of: abdominal obesity; elevated plasma triglycerides; low HDL 
cholesterol; hypertension or anti-hypertensive treatment; and high fasting plasma glucose): 
one highest quality study showed that metabolic syndrome predicted any cause dementia in 
people with aMCI41. 
Summary  
 There is grade 2 evidence that diabetes increases the risk of AD in people with aMCI 
or any cause dementia in people with any type or non-amnestic MCI [pooled OR 1.65 
(95% CI 1.12 to 2.43), and that prediabetes predicted conversion from any type MCI 
to all cause dementia. Evidence across epidemiological and clinical, and aMCI and 
any type MCI studies appeared consistent. 
 There is grade 2 evidence that hypertension does not predict conversion from any 
type MCI to all cause dementia from epidemiological and clinical studies [pooled OR 
1.05 (0.6 to 1.85)], but evidence regarding conversion from aMCI to AD was 
inconsistent. 
 There is grade 2 evidence that hypercholesterolemia is not associated with risk of 
conversion from any type MCI to all cause dementia, while evidence for the risk of 
AD in people with aMCI was inconsistent. 
 There is grade 1 evidence that smoking is not associated with risk of conversion from 
aMCI to AD, or any type MCI to all cause dementia after controlling for age.  
 There is grade 2 evidence that heavy alcohol use predicts conversion from any type 
MCI to dementia, and inconsistent evidence about whether moderate alcohol use 
predicts risk of dementia.  
 There is grade 2 evidence that the metabolic syndrome predicts a greater risk of all 
cause dementia in people with aMCI. 
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Neuropsychiatric symptoms (NPS) 
Any NPS: Three small clinical studies found NPI total scores were not associated with risk of 
conversion from any type MCI to all cause dementia42;43 or aMCI to AD44 (pooled effect size 
0.0, -0.39 to 0.40). A higher quality epidemiological study also found no association of total 
Neuropsychiatric Inventory (NPI) score with conversion from any type MCI to all cause 
dementia, after controlling for age and education45, while one small additional clinical study 
found that it did predict conversion from any type MCI to AD46. 
Five studies compared the proportion of participants reaching a threshold of NPS who 
converted from any type MCI to all cause dementia47-50 or AD46. Four studies reported the 
proportion scoring one or more on the NPI47, while a fifth reported the proportion scoring four 
or more NPS on an unvalidated scale49. The four clinical studies all reported a trend or 
significant association between having NPS and conversion (pooled OR 3.11, 1.38 to 7.02). 
One of these studies also reported that those who scored in the middle and higher tertile of 
NPI scores (compared to the lowest) had a greater risk of converting from any type MCI to 
all cause dementia50. The only epidemiological study found the reverse trend47 so was 
excluded from meta-analysis, although even when included the result remained significant.   
Depressive symptoms: Twenty studies reported whether depressive symptoms predicted 
conversion, and results from 17 were included in meta-analyses. Six clinical studies in 
people with aMCI, reported mean scores on depression rating scales, and only one51 found 
a statistically significant difference between baseline scores of those who did and did not 
convert to dementia35;52 or AD44;51;53;54 [pooled standardised effect size 0.21, -0.19 to 0.60; 
see Figure 2d]. Figure 2c shows unadjusted OR for having depressive symptoms from 13 
studies [pooled OR 1.35, 0.89 to 2.06]. There was heterogeneity, with the epidemiological 
studies reporting conversion from any type MCI consistently finding depressive symptoms 
predicted all cause dementia, while findings from studies in aMCI and clinical study findings 
were less consistent. These analyses omitted three studies; two large, higher quality 
epidemiological and clinical studies respectively which found scoring six or more on the GDS 
predicted a higher risk of dementia in people with any type MCI; and that scoring in the 
middle or highest compared with the lowest tertile of the GDS also predicted a higher risk of 
any cause dementia, and scoring in the middle compared to the lowest predicted AD in 
people with any type MCI diagnosis made by an experienced clinician25;50; and a clinical 
study that reported a non-significant finding42. 
Apathy: This was examined in five clinical studies [pooled OR 1.62, 0.63 to 4.17; Figure 
2f].In the largest study, reporting apathy symptoms but not depressive symptoms on the 
relevant validated Geriatric Depression Score (GDS)-15 subscales55 predicted conversion 
from aMCI to AD, but apathy symptoms alone were not a significant predictor (Figure 2e). 
Results from four other small studies were mixed; NPI apathy subscale scores and apathy 
assessed using standard criteria was associated with conversion from aMCI to AD56 with a 
similar but non-significant trend reported in a second study57. Two small studies examined 
whether apathy predicted conversion from any type MCI to all cause dementia. Participants 
meeting Marin’s diagnostic criteria for apathy at clinical interview had a seven-fold greater 
odds of developing dementia58, but having symptoms of apathy on the Chinese NPI59 was 
not associated with developing dementia.  
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Anxiety: Three studies investigated the association of anxiety symptoms with conversion 
from aMCI to AD. In one higher quality epidemiological study, more anxiety on the CPRS 
subscale predicted AD60. In three clinical studies, anxiety scores on validated scales did not 
predict conversion57;44;53 [pooled OR from clinical studies -0.11, -0.34 to 0.11].  
Summary 
 There is grade 1 evidence that more depressive symptoms predicted conversion 
from any type MCI to all cause dementia from epidemiological studies, but 
inconsistent evidence from clinical studies and about whether they predicted 
conversion from aMCI to AD or dementia.  
 There is grade 2 evidence from clinical studies that people with any type MCI 
reporting NPS, but not the overall levels of symptoms, predicted conversion to all 
cause dementia. 
 There is inconsistent evidence about whether anxiety symptoms are associated with 
conversion from aMCI to AD, or whether apathy predicted the risk of conversion from 
aMCI to AD, or any type MCI to dementia.  
Dietary factors 
In a single, higher quality epidemiological study, adherence to a Mediterranean diet (low in 
meat and dairy products, high in fruits, vegetables, legumes, cereals, and fish) predicted a 
lower risk of conversion from aMCI to AD61. 
Folate: Two studies (epidemiological and clinical) have found that higher serum folate 
predicts a lesser risk of conversion from any type MCI to all cause dementia27;62;62 and a third 
showed a non-significant trend towards this63. In the former study, self-reported folate and 
vitamin B12 supplement use predicted a lesser risk of dementia compared with non-users, 
but not inconsistent users but serum B12 levels did not predict dementia.  
Higher homocysteine levels (associated with vascular inflammation) predicted conversion 
from aMCI to AD in a clinical study32, and conversion from any type MCI to all cause 
dementia in one64, but not a second epidemiological study62.  
Higher serum levels of copper predicted conversion from aMCI to AD in a single, good 
quality study; it has been suggested that altered copper homeostasis is a pathogenic 
mechanism in AD65.  
Summary 
 There is grade 2 evidence that following a Mediterranean diet decreases risk of 
conversion from aMCI to AD. 
 There is grade 2 evidence that lower folate serum levels predict conversion from any 
type MCI to all cause dementia. 
 There is inconsistent evidence about whether homocysteine serum levels predict 
dementia. 
Education 
In seven studies, years of education for people with aMCI did not predict conversion to 
AD20;31;38;44;53;66;67 or any cause dementia23;35;54 on unadjusted analyses [pooled effect size -
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0.03, -0.16 to 0.10]. Three further studies found that education did not predict conversion 
from aMCI to AD68;69 or any cause dementia24;70. Only two studies found that education did 
predict conversion to AD in people with aMCI (neither could be included in meta-analyses); 
one found that those who converted within 20 months were more likely to have had less than 
10 years of schooling than those who did not69; the second that those with more education 
had an increased risk of AD71. 
Amount of education received did not predict conversion from any type MCI to all cause 
dementia in 15 of 16 studies to examine this29;31;45;59;62;72-80. In one epidemiological study, 
less education predicted a greater risk of dementia26. Two studies reported the association 
of education with conversion from any type MCI to AD. One found that more education 
decreased43;43 and one that it increased81 risk. Only five of the studies in people with any 
type MCI (from four datasets) reported years of education in people who did and did not 
convert from any type MCI to dementia, and the pooled unadjusted effect size from these 
studies was not significant (-0.30, -0.63 to 0.01)43;53;59;67;80. Figure 2g shows the overall 
pooled OR for years of education as a predictor of dementia (-0.11, -0.26 to 0.03) from aMCI 
and any type MCI studies.  
Summary 
 There is grade 1 evidence from clinical and epidemiological studies that amount of 
education does not predict conversion from any type MCI to all cause dementia, or 
from aMCI to AD. 
 
Other significant predictors 
More physical activity82, low Body Mass Index (BMI)27 or atrial fibrillation83 predicted 
conversion from any type MCI to all cause dementia in clinical studies. “Antidementia drugs” 
reduced the risk of conversion from any type MCI to all cause dementia in a clinical84, but not 
in a higher quality epidemiological study25. Oestrogen replacement therapy predicted shorter 
time to conversion from any type MCI to all cause dementia (mean 1.3 +/-0.5 years, versus 
mean of 2.8 in whole sample; p=0.0029), but not greater likelihood of dementia36. 
Anticholinergic drug use predicted conversion from any type MCI to all cause dementia after 
controlling for age among women, but not men in an epidemiological study26.  
Discussion 
Diabetes and prediabetes were associated with an increased risk of conversion from aMCI 
to AD and the risk was lower in one study for those receiving treatment for diabetes. 
Metabolic syndrome and pre-diabetes predicted all cause dementia in people with aMCI and 
any type MCI respectively in one study. Older people without MCI who have diabetes are 
known to be at increased risk of AD, vascular and all cause dementia17. Our review shows 
that diabetes remains an important predictor of AD in people with aMCI and suggests it may 
be helpful to ensure this is detected and treated.  
 
Diabetes and the metabolic syndrome are associated with atherosclerosis and brain infarcts 
and glucose-mediated toxicity causes microvascular abnormalities. Hyperinsulinemia, a 
symptom of type II diabetes or result of insulin replacement, has been associated with 
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cognitive decline and AD85, probably mediated by vascular disease and possible direct brain 
effects. Cerebral insulin receptors are abundant in the hippocampus and the cortex, and 
insulin inhibits beta amyloid degradation, the main product of the AD process85. Evidence of 
impaired insulin receptor activation in AD brains86 has led to suggestions AD may be “an 
insulin resistant brain state”17.  
Similar mechanisms could explain the finding from one of the reviewed studies that 
adherence to a Mediterranean diet predicts a lower risk of aMCI to AD conversion. 
Mediterranean diet adherence is associated with fewer vascular risk factors, and reduced 
plasma glucose and serum insulin levels, insulin resistance and markers of oxidative stress 
and inflammation61. Higher folate levels predicted a lesser risk of conversion from any type 
MCI to all cause dementia, and they have also been shown to predict lower medial temporal 
lobe atrophy62. These findings are similar to those in populations not selected for presence 
of mild cognitive impairment, that lowering saturated fat intake87, increasing vegetable 
consumption88 and Mediterranean diet adherence89 appear to protect against dementia. We 
did not find that hypercholesterolaemia or hypertension predicted conversion to dementia. In 
a systematic review of predictors of dementia in non-MCI population, hypertension 
decreased risk of vascular dementia90, but relatively few of the studies reported vascular 
dementia as an outcome. Midlife, but not late life total cholesterol levels have been shown to 
predict AD and any cause dementia91 in general populations, so for hypercholesterolaemia 
and perhaps other vascular risk factors, intervention may only be effective if delivered before 
the onset of MCI. 
A third to three-quarters of people with MCI have NPS; most commonly depression, anxiety, 
apathy and irritability92. NPS predicted conversion from any type MCI to all cause dementia. 
NPS may be etiologic for dementia, for example through neuroendocrine axis activation; or 
interact synergistically with a biological factor, such as genetic predisposition; either of these 
putative relationships suggest that treating NPS could theoretically delay dementia. 
Alternatively, NPS may indicate more severe pathology93. Greater anterior cingulum 
pathology in people with MCI and AD has been associated with more irritability, agitation, 
dysphoria, apathy, and night time behavioral disturbances94. Serotonergic dysfunction is 
probably of particular relevance to NPS, including depression and aggression95, suggesting 
serotonergic drugs might theoretically treat NPS and reduce risk of progression; in one 
preliminary study fluoxetine improved cognition in people with MCI compared with placebo 
after 8 weeks96. We found that depressive symptoms predicted conversion from any type 
MCI to all cause dementia in epidemiological studies, but evidence from clinical studies was 
inconsistent. This might be due to lack of power in the clinical studies. In non-MCI 
populations, affective disorders appear to be a risk factor for dementia, as well as a 
prodromal symptom, in clinical and epidemiological studies97.  
We found higher quality evidence that amount of formal education received does not predict 
dementia in MCI. According to the cognitive reserve model, education delays clinical 
manifestations of brain pathology, so people with more education have worse neuropathology 
for any level of cognitive impairment,98 and in the older general population, low education does 
predict dementia14. While the onset of MCI may be delayed in those with more education, our 
review indicates that progression to dementia is not delayed once MCI is diagnosed, 
consistent with cognitive reserve theory. 
Limitations  
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We prioritised positive findings, but also described null results reported in more than one 
higher quality study. Lack of evidence of prediction is not evidence of lack of prediction. Many 
factors found to be associated with dementia risk in populations in whom most did not have 
MCI, for example physical activity and omega-3 fatty acids14 were not studied in included 
papers, or insufficiently studied, e.g. homocysteine14. We excluded studies where the outcome 
was progression of cognitive impairment rather than incident dementia. There is known to be 
a degree of inaccuracy in dementia diagnoses in clinical and epidemiological studies which 
may have compromised the validity of some study findings. Almost all studies included any 
cause dementia or AD as outcomes, rather than other subtypes; few reported vascular 
dementia as an outcome and predictors, especially vascular risk factors, are likely to differ 
from those of degenerative dementias such as AD. 
Future Research 
Associations in naturalistic, longitudinal studies do not imply causation; we do not know 
whether preventing or treating diabetes, NPS and depression, where possible, or 
Mediterranean diet adherence, might reduce the risk of AD or dementia. In many people with 
MCI, vascular risk factors and dietary habits are longstanding, and pathology may not be 
reversible. In the absence of effective MCI treatments, however, our findings suggest that 
managing components of the metabolic syndrome, dietary interventions and social 
interventions are logical targets for future trials.  
 
Methodological challenges for MCI trials include defining study population. Only two- thirds 
of people with MCI progress to dementia in their lifetime99, limiting the power of secondary 
prevention studies that recruit MCI populations. The heterogeneity and instability of the MCI 
diagnosis militate against finding positive results in MCI trials. Availability of biomarkers may 
enable future trials to recruit participants according to disease process rather than clinical 
deficits; in a recent study, a panel of 10 proteins predicted progression from MCI to AD with 
an accuracy of 87%100. Biomarkers may also allow participants to be recruited when the 
pathological process is less advanced and treatments more effective. Incident dementia is 
often the primary outcome as dementia prevention is a clear goal, but Schneider has 
suggested it is a problematic endpoint because many participants would be on the cusp of 
dementia and dementia onset is influenced by numerous biological and environmental 
factors101.  
Conclusions 
Further good quality RCTs are necessary to identify evidence-based dementia prevention 
strategies, and the increasing availability of biomarkers will assist in recruitment of more 
homogenous populations with high likelihood of dementia conversion, improving trial 
efficiency. In our recent review of RCTs we found no consistent evidence for any intervention 
preventing conversion from MCI to dementia. The findings of this systematic review suggest 
that managing diabetes, components of the metabolic syndrome and dietary interventions 
are logical targets for future trials.  
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Figure 1: PRISMA Flow Diagram 
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Figure 2: Meta-analysis plots [random effects] 
2a: Odds ratios for diabetes 
0.01 0.1 0.2 0.5 1 2 5 10 100 
Velayudhan (Clin, aMCI>D) 4.86 (1.26, 17.79) 
Solfrizzi 2004 (Ep, aMCI>D) 0.51 (0.01, 3.97) 
Ravaglia (Clin, aMCI>AD) 0.80 (0.18, 2.82) 
Prasad (Clin, aMCI>AD) 2.10 (0.67, 6.48) 
Li 2011 (Ep, aMCI>AD) 1.80 (1.21, 2.69) 
Artero (Ep, MCI>D) 2.00 (1.30, 2.99) 
Xu 2010 (Ep, MCI>D) 0.67 (0.21, 1.95) 
combined [random] 1.65 (1.12, 2.43) 
odds ratio (95% confidence interval) 
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Figure 2b: Odds ratios for current hypertension 
0.1 0.2 0.5 1 2 5 10 100 
Korf (Clin, MCI>D) 0.45 (0.13, 1.45) 
Oveisgharan (Ep, MCI>D) 0.81 (0.61, 1.08) 
Artero (Ep, MCI>D) 1.96 (1.25, 3.21) 
Ravaglia (Clin, aMCI>AD) 1.23 (0.58, 2.57) 
Solfrizzi 2004 (Ep, aMCI>D) 1.86 (0.45, 10.97) 
Prasad (Clin, aMCI>AD) 0.92 (0.31, 2.71) 
Li 2011 (Ep, aMCI>AD) 1.61 (1.14, 2.26) 
combined [random] 1.19 (0.81, 1.73) 
odds ratio (95% confidence interval) 
Figure 2c Effect size , depressive symptoms 
-1 1 2 
Visser 2000 (Clin, aMCI>AD) 
 
Mackin (Clin, aMCI>D 
Devier (Clin, MCI>D) 
 
Rozzini 2007  (Clin, aMCI>AD) 
 
Gabryelewicz (Clin, MCI>D) 
  0   
DL pooled effect size = 0.206145  (95% CI = -0.191433 to 0.603722) 
Modrego (Clin,aMCI>AD) 
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Figure 2d: Odds ratios for depressive symptoms 
0.01 0.1 0.2 0.5 1 2 5 10 100 
Richard 2012 (Clin, aMCI>AD) 1.86 (1.21, 2.87) 
Palmer 2010 (Clin, aMCI>AD) 0.95 (0.23, 3.41) 
Visser 2000 (Clin, aMCI>AD) 0.57 (0.14, 2.09) 
Fellows (Clin, aMCI>AD) 0.76 (0.30, 1.94) 
Modrego (Clin, aMCI>AD) 11.91 (4.11, 38.57) 
Velayudhan (Clin, aMCI>D) 1.59 (0.38, 6.24) 
Panza 2008 (Ep, aMCI>D) 0.83 (0.23, 3.12) 
Caracciolo (Ep, aMCI>D) 3.28 (0.60, 22.48) 
Chilovi (Clin, MCI>D) 0.28 (0.09, 0.78) 
Korf (Clin, MCI>D) 0.48 (0.17, 1.35) 
Chan (Clin, MCI>D) 2.18 (0.99, 4.57) 
Artero (Ep, MCI>D) 1.95 (1.36, 2.77) 
Richard 2013 (Ep, MCI>D) 1.70 (0.91, 3.08) 
combined [random] 1.35 (0.89, 2.06) 
odds ratio (95% confidence interval) 
Figure 2e Apathy Odds ratio  
0.01 0.1 0.2 0.5 1 2 5 10 100 
Chan (Clin, MCI>D) 0.34 (0.06, 1.14) 
Chilovi (Clin, MCI>D) 2.75 (1.03, 7.21) 
Robert (Clin, aMCI>AD) 2.39 (0.89, 6.66) 
Richard 2012 (Clin, aMCI>AD) 0.72 (0.47, 1.09) 
Palmer 2010 (Clin, aMCI>AD) 8.67 (1.83, 39.44) 
combined [random] 1.62 (0.63, 4.17) 
odds ratio (95% confidence interval) 
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Figure 2f: Odds ratio, Neuropsychiatric symptoms 
0.01 0.1 0.2 0.5 1 2 5 10 100 
Rosenberg 2013 (Clin, MCI>D) 1.86 (1.53, 2.26) 
Edwards 2009 (Clin, MCI>D) 1.61 (0.86, 3.10) 
Taragano (Clin, MCI>D) 7.51 (3.96, 14.29) 
Teng (Clin, MCI>AD) 17.55 (1.60, infinity) 
Brodaty 2012 (Epi, MCI>D) 0.64 (0.07, 3.25) 
combined [random] 2.52 (1.18, 5.37) 
odds ratio (95% confidence interval) 
Figure 2g: Effect size for years of education 
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Prasad (Clin, aMCI>AD) 
Fellows (Clin, aMCI>AD) 
Ye 2012 (Clin, aMCI>AD) 
Visser 2000 (Clin, aMCI>AD) 
Velayudhan (Clin, aMCI>D) 
Mackin (Clin, aMCI>D) 
  0   
DL pooled effect size = -0.117011  (95% CI = -0.26397 to 0.029947) 
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Key for all tables 
Unless stated, dementia diagnoses met DSM-IV (or DSM-IIIR) criteria for dementia, or 
NINCDS/ARDRA criteria for possible or probable AD, or NINDS-AIREN criteria for possible 
or probable vascular dementia, or DLB Consortium criteria for Lewy body disease or 
Manchester-Lund criteria for frontotemporal dementia 
*MCI criteria for diagnosis – in addition to objective cognitive (or for aMCI) impairment 
on testing; absence of dementia and ADL impairment 
** Whether meets validity criteria in method: 1. A defined representative sample of 
participants assembled at a common (usually early) point in the course of their 
disease, or recruited to be representative of the general older population, with a 
response rate of at least 60% of eligible potential participants. 2.Participant follow-up 
for at least a year, with at least 70% followed up. 3.Criteria for diagnosing MCI and 
dementia were objective or applied in a ‘masked’ fashion. 
AB= abstinence; AD=Alzheimer’s Disease; ADASCog= Alzheimer's Disease Assessment 
Scale-cognitive subscale; ADL= Activities of Daily Living; aMCI= Amnestic Mild Cognitive 
Impairment; APOE=Apolipoprotein E; b/l= baseline; BMI= Body Mass Index; bp= Blood 
Pressure; CDR=Clinical Dementia Rating scale; CERAD=Consortium to Establish a Registry 
for Alzheimer's Disease; CAD= coronary artery disease; ChEI= Cholinesterase Inhibitor; 
C/NC: Converters (to Dementia) versus Non-Converters; CPH= Cox Proportional Hazards; 
CSF= Cerebrospinal Fluid; CIRS=Cumulative Illness Rating Scale; CVA= Cerebrovascular 
Accident; DM= Diabetes Mellitus; FHx= Family History of Dementia; GDS=Geriatric 
Depression Scale; GLM= Generalized Linear Model; HD=Heart disease; HDL= High Density 
Lipoprotein; HR=Hazard Ratio; HRT= Hormone replacement Therapy; HT=Hypertension; 
IADL= Instrumental Activities of Daily Living; IQ= Intelligence Quotient; IWG=International 
Working Group; KM= Kaplan-Meier analysis; LDL= Low Density Lipoprotein; LEDS=Life 
events and Difficulties Schedule; LR= Logistic Regression; MCI=Mild Cognitive Impairment; 
MMSE=Mini Mental State Examination; MADRS=Montgomery–Åsberg Depression Rating 
Scale; MD-MCI= Multi domain MCI; MeDi= Mediterranean Diet; MPS= Mild Parkinsonian 
Symptoms; N= number; NINCDS=National Institute of Neurological and Communicative 
Disorders and Stroke;  NP= Neuropsychological test score; NPI= Neuropsychiatric Inventory; 
NS= Non Significant; OR=Odds Ratio; (P)= Petersen criteria; CT=Randomised Controlled 
Trial; RR= Risk or Rate Ratio; SD= Standard Deviation; SMC=Subjective memory 
impairment; S/IMC= Subjective or informant base memory impairment; SCC=Subjective 
cognitive complaint; S/ICC= Subjective or informant-based cognitive complaint; T1/T2 = 
Time 1 and Time 2; TIA= Transient Ischemic Attack; UC: Univariate comparisons; 
VaD=Vascular Dementia; WMS-R=Wechsler Memory Scale-Revised; WS= Figure shows 
response or follow-up rate for whole cohort, not specifically those with MCI 
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Table 1: Characteristics and findings of higher quality epidemiological studies  
Study  Recruitment source % 
recru
ited 
FU, 
year
s 
MCI 
subtypes 
and 
criteria* 
N 
(outcome 
if not 
dementia
) 
% 
follo
w-up 
Analysis adjusted 
for.. 
Model Prognostic factor Statistics (for all 
MCI unless stated) 
Han 73 Random sampling in 
Seongnam, Korea 
 
64% 1.5 All 
IWG 
criteria 
140 
 
71% age, sex, education, 
time, APOE, 
medications,MMSE, 
GDS, CIRS 
LR Years education, 
chronic illness, GDS, 
medications  
All ns (stats not 
given) 
Li 18 Long term residents aged 
55+ without depression from 
10 randomly selected 
communities in the city of 
Chongqing 
 
71% 5  aMCI 
SMC 
638 
(AD) 
76% age, sex, 
education, occupation, 
depressive symptoms, 
APOE4, baseline 
MMSE, and ADL score 
CPH Hypertension HR 1.84(1.19–2.84) 
p=0.006 
Diabetes HR 1.62 (1.00–2.62) 
p=0.049 
Hypercholesterolem
ia (HC) 
HR 1.11 (1.04–1.18), 
p=0.001 
Obesity HR 1.15 (0.45–2.92) 
p=0.78 
Myocardial infarction HR 1.05 (0.67–1.65) 
p=0.83 
Atrial fibrillation HR 1.09 (0.54–2.20) 
p=0.815 
Current smoking HR 1.09 (0.67–1.79) 
p=0.73 
Daily drinking HR 1.10 (0.69–1.75) 
p=0.700 
Vs untreated: HT 
treated  
HR 0.85 (0.80–0.90) 
p=0.001 
Diabetes treated HR 0.87 (0.83–0.91) 
p=0.001 
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HC treated HR 0.88 (0.83–0.93) 
p=0.001 
Cease smoking HR 0.91 (0.49–1.70) 
p=0.78 
Cease drinking HR 0.89 (0.62–1.27) 
p=0.51 
Luck 25 A random sample selected 
from people aged 75+ in 6 
German towns referred by 
General Practitioners 
 
75% 4.5  All 745 71% Age, gender, cognition 
and other factors listed 
CPH Living alone  HR 1.42 (0.95–2.14) 
0.09 
Not married currently HR 1.52 (0.71–3.23 
Diabetes Mellitus HR 1.35 (0.94–1.96) 
0.11 
Hypertension HR 1.05 (0.70–1.59) 
0.81 
Cardiac arrhythmia HR 0.80 (0.53–1.21) 
0.30 
Coronary heart 
disease 
HR 1.25 (0.82–1.90) 
0.29 
Myocardial infarction HR 0.59 (0.31–1.15) 
0.12 
Peripheral artery 
disease 
HR 0.95 (0.53–1.69) 
0.85 
Carotid artery 
stenosis 
HR 0.61 (0.21–1.79) 
0.37 
TIA HR 1.55 (0.91–2.64) 
0.10 
Hyperlipidaemia HR 1.27 (0.82–1.95) 
0.29 
Hypercholesterolemia HR 1.16 (0.76–1.78) 
0.48 
Epilepsy HR 0.14 (0.02–1.12) 
0.06 
Hyperthyroidism HR 0.94 (0.45–1.96) 
0.87 
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Hypothyroidism HR 0.88 (0.34–2.32) 
0.80 
GDS 6+ HR 1.60 (1.03–2.48) 
0.04 
Impaired vision HR 1.02 (0.65–1.58) 
0.95 
Impaired hearing HR 1.44 (1.01–2.05) 
0.05 
Former vs non-
smoker 
HR 0.69 (0.45–1.08) 
0.10 
Current vs non-
smoker 
HR 0.94 (0.47–1.87) 
0.86 
Normal vs no drinking HR 1.13 (0.78–1.65) 
0.51 
Harmful vs no 
drinking 
HR 0.47 (0.06–3.59) 
0.46 
Antidementia drugs HR 1.19 (0.78–1.84) 
0.42 
Peltz 78 Members of a large USA 
retirement community, aged 
90+  
61% 2.5  All 395 94% Age CPH Education (being 
college graduate) 
HR 1.03 (0.6–1.6) 
Richard10
2 
 Participants identified from 
a probability sample of 
Medicare beneficiaries in 
New York 1999-2001 
98.9
% 
5.1 All MCI 
SMC 
320 74% Age, sex education, 
ethnicity 
CPH Depression (CES-D 
4+) 
HR 1.8 (1.0-3.1) 
Scarmea
s 61 
Participants identified (via 
ethnicity and age 
stratification) from a 
Medicare probability sample 
of beneficiaries in New York 
in 1992 and 1999 
64% 4.3  aMCI 
all 
SMC 
482 
(AD) 
85% cohort, age, sex, 
ethnicity, education, 
APOE, caloric intake, 
BMI, 
CPH Middle vs lowest 
MeDi adherence 
tertile 
aMCI/MCI: HR 0.48 
(0.22-1.04; P=.06); 
HR=0.55 (0.34-0.90); 
P=.01 
Highest vs lowest 
tertile 
aMCI/MCI: 0.71 
(0.32-1.59) P=.41; 
0.52 (0.30-0.91) 
P=.02 
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Panza 103 Data from Italian 
Longitudinal Study of aging, 
a random sample population 
survey of people aged 65-84 
from 8 municipalities 
 
83% 3.5  aMCI 
normal 
MMSE for 
age/ 
education 
121 87% Sex, age, education, 
HT, CAD, smoking, 
stroke, DM, HC 
Poisso
n  
Italian GDS 10+ Rate ratio 1.42 (0.48–
4.23)  
Solfrizzi 
39 
Gender, age education CPH <1 drinks /day 
alcohol vs 
abstinence (AB) 
HR 0.15 
(0.03–0.78) 
1-2 drinks/day vs AB  HR 0.47 (0.08–2.73) 
2+ drinks/day vs AB HR 0.44 (0.05–4.06) 
<1 drinks /day wine 
vs AB 
HR 0.15 (0.03–0.77) 
1-2 drinks/day wine 
vs AB  
HR 0.44 (0.07–2.64) 
2+ drinks/day wine vs 
AB 
HR 0.36 (0.03–4.26) 
Solfrizzi 
41 
    Sex, age, education, 
GDS, alcohol, 
smoking, fibrinogen, 
cholesterol, HD, stroke 
CPH Metabolic syndrome
  
HR 7.80 (1.29–47.20) 
Solfrizzi 
24 
None Univari
ate 
Poisso
n 
regress
ion 
Education (<4 years) RR 0.79 (0.23–3.44) 
No hypertension RR 1.74 0.46–9.74 
No coronary artery 
disease 
RR 1.71 0.32–6.78 
No type II DM RR 0.54 0.01–3.62 
Never smoked RR 0.46 0.08–1.74 
Cholesterol, vs <4.5: 
4.6–5.2 
RR 0.75 0.11–4.43 
5.2-6.0 RR 0.97 0.18–5.20 
>6.0 RR 0.75 0.11–4.43 
HDL cholesterol (vs 
<1.0): 
1.0–1.2 
RR 1.37 0.27–8.84 
1.2–1.4 RR 1.67 0.32–10.73 
>1.4 RR 0.30 0.01–3.75 
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St John72 Random sample of residents 
aged 65+ of Manitoba, 
Canada 
61% 5  All; 
Modified 
MMSE < 
78, CIND 
on exam  
85 
 
90% Sex, age, education, 
MMSE, depression, 
function, SMC 
LR self-rated health good  OR 1.05 (0.30- 3.72) 
Educations (years) OR 0.88 (0.74- 1.05) 
Caracciol
o104 
Kungsholmen Project,  
population-based 
prospective cohort study of  
all registered inhabitants 
aged 75+  in a Stockholm 
district, Sweden, in 1987 
76% 3  All, 
aMCI, 
Non aMCI 
 
160  
 
85%  age, sex, education 
and APOE 
CPH Perceived sadness/ 
low mood at baseline 
aMCI: HR 5.9 (1.4 to 
25.0) 
All MCI: 1.4 (0.8 to 
2.4) 
Xu22 9  302 
 
90% age, sex, education, 
MMSE, survival, BMI, 
HD, stroke, bp, APOE 
antihypertensive drugs  
CPH Prediabetes (blood 
glucose 7.8 –11.0 
mmol/l) 
Dementia: HR 4.96 
(2.27–10.84); AD: 
5.73 (2.43–13.5) 
Diabetes Mellitus HR 2.87 (1.30–6.34) 
AD: HR 2.83 (1.18–
6.78) 
DM or preDM aMCI: HR 2.24 (0.75– 
6.71) 
non a-MCI: 4.31 
(1.97–9.42) 
Palmer60 3  aMCI 
MMSE >1
9; SMC 
47 
(AD) 
92.4
% 
WS 
age, sex, and 
education 
 Mood symptoms RR 0.9 (0.6–1.5) 
Motivation symptoms RR 1.1 (0.7–1.8) 
Anxiety symptoms RR 1.8 (1.2–2.7) 
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Table 2: Characteristics and findings for other epidemiological studies  
Study  Recruitment source FU, 
yea
rs 
N  Type 
of MCI 
Outc
ome 
 
Analysis 
adjusted for.. 
Model Prognostic factor Statistics Validi
ty* 
1 2 3 
Artero26 Random sample recruited 
from French electoral roles 
4  
 
28
82 
All 
IWG 
criteria 
S/ICC 
 
Dem
entia  
None ** 
UC , 
LR 
Hypertension; 
coffee, alcohol, 
tobacco use; HRT 
Hypercholesterolae
mia; head trauma; 
depression; herpes; 
anaesthesia; cancer; 
diabetes, vascular 
risks, asthma, 
antidepressants, 
subjective health, 
insomnia, BMI >27, 
appetite loss, social 
isolation,  
Not significant on 
univariate 
comparisons for men 
or women 
(p>0.01; actual stats 
not shown) 
n y y 
IADL 
APOE 
Age 
Stroke (men) 
Gender-
stratified 
Subclinical 
depression 
Women: OR 1.95 
(1.06-3.58); p<0.03 
Men NS  
Anticholinergic 
drugs 
Women: OR 1.78 
(1.00 -3.18) p=0.04; 
Men: NS  
Low education 
level 
Men: OR 2.26 (1.25 
to 4.06); p<0.01; 
Women: 2.16 (1.31 to 
3.56); p<0.01 
Blasko 62 
 
People recruited for a 
population-based study of 
 5  
 
81 
 
 Dem
entia  
 
none LR Self-reported 
folate/B12 
supplements vs (1) 
(1) OR 0.15, 0.03-
0.77 p=0.023 (2) OR 
1.8 (0.6-5.6), p=0.330 
n y y 
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75 year-olds in Vienna, 
Austria 
 
non-users (2) 
inconsistent users 
Serum 
homocysteine and 
B12 levels  
Not significant 
sex, APOE, 
education, 
creatinine, folate  
LR Ln of serum folate  OR 0.17 (0.04-0.69), 
p=0.013 
n y y 
Education (years) OR 0.77 (0.58-1.01), 
p=0.062 
Brodaty47 70–90 years  on Sydney 
electoral roll  
2  319 All (P) Deme
ntia  
age, sex, 
education 
LR NPI score >=1 OR 0.57 (0.1–2.8), 
p=0.49 
n y y 
Beaudreau
45 
Adults aged 70+ in USA 
aging study recruited to 
represent population 
4 180 All, 
panel 
diagno
sis 
Deme
ntia  
Age , APOE 
Education, NPI 
LR Education (years) OR 0.97 (0.88, 1.07) 
p=0.56 
n y y 
NPI total scores OR 1.01 (0.97, 1.06) 
p=0.61 
Chan et al 
59 
People aged 60+ from Hong 
Kong, and from old age 
hostels & day centres 
2  
 
321 All 
SMC 
 
Deme
ntia  
MMSE, 
education, age, 
gender 
LR Education (years) OR 0.98 (0.87–1.09) 
p=0.67 
n y y 
depression/dysphor
ia 
OR 2.40 (1.05–5.46) 
p=0.04 
apathy/indifference OR 0.31 (0.09–1.13) 
p=0.08 
aberrant motor 
behaviour 
OR 9.96 (0.57–174.42) 
p=0.12 
Lopez 105 Random sampling of 
Pittsburgh Medicare  
Me
an 
4.3  
136 aMCI 
and 
MD-
MCI 
 Nil **UC > High school 
education, No. (%) 
NS, chi2=2.43 n y y 
Meyer 80 Participants who developed 
MCI during longitudinal 
study 
m
ea
n 
3.
9  
 
73 SMC 
All 
AD 
and 
vasc
ular 
dem
entia 
None **UC Education (years) 
 
 
AD, C/NC: 11.54 vs 
14.57, p<0.01 
VaD, C/NC: 13.13 vs 
14.57 
n y y 
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Oveisghar
an 30 
 
Participants in Canadian 
Study of Ageing, recruited 
to represent population 
 
5  99
0 
All Dem
entia 
Age, sex, 
APOE, cognitive 
impairment 
subtypes and 
interaction terms 
LR Hypertension NS (results not given); 
in subgroup with 
executive 
dysfunction, 
hypertension, 57.7%  
vs normotension 
28.0%,P=.02), in UC 
y n y 
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Table 3: Characteristics and findings for clinical studies  
Study  Recruitment source FU, 
yea
rs 
N  Type 
of MCI 
Outc
ome 
 
Analysis 
adjusted for.. 
Model Prognostic factor Statistics Validit
y (see 
metho
d) 
1 2 3 
Abner 29 Recruits from Kentucky AD 
center who entered a 
longitudinal study (BRAiNS) , 
who agreed to brain 
donation, when cognitively 
intact and developed MCI  
10 101 All, 
aMCI 
S/ICC, 
Intact 
global 
cogniti
on 
Deme
ntia 
APOE, age, 
gender, family 
history, 
education, 
hypertension, 
MCI duration 
Markov 
chain 
Hypertension RR 0.30 (0.10–0.93) n y y 
Abner37 649  
 
Vs never smoked: 
<1 – 10 pack-years 
vs. never smoked  
OR 0.28 (0.08–0.94) 
p= 0.039 
n y y 
10-20 pack-years  OR 0.28 (0.08–0.94) 
0.04 
n y y 
≥20 pack-years OR 0.31 (0.13-0.71) 
p=0.005 
n y y 
Kryscio75 554 Deme
ntia 
APOE, age, 
gender, family 
history, education 
polyto
mous 
LR 
≤12 vs ≥16 years 
education 
 
Amnestic: OR 1.00 
(0.32–3.14) Mixed: 
0.38 (.05–3.12) 
n y y 
13-15 vs ≥16 years 
education 
Amnestic: OR 0.92 
(0.39–2.16)Mixed: 1.56 
(0.64–3.79) 
n y y 
Kryscio36 Years 
to 
diagno
sis 
HRT 
Smoker at baseline 
Mean (SD) 1.3±0.5, 
p=0.0029  
n y y 
0.66±0.26, p=0.043 n y y 
Alefret68 Clinical convenience sample 4 42 aMCI(
P) 
AD Age, gender CPH 2ndry  school 
education 
HR 1.80 (0.70–4.67) n y y 
Amieva70 Participants in drug RCT, no 
history of depression or 
stroke 
2  
 
90 SMC 
aMCI 
Deme
ntia 
 
- **UC % primary school 
diploma 
C/NC 89.7% vs 88.5% 
(p=0.99) 
n y y 
Aretouli et 
al 76 
Research centers and clinics 
in USA 
2  
 
104 All Deme
ntia 
(CDR
≥1) 
- **UC Education (years) F(1,92)=0.02, p=.890 n y y 
29 
 
Barabash69 Consecutive, Madrid Memory 
Unit  
1.7  89 aMCI, 
SMC 
AD  Age, APOE, 
genetics  
CPH < 10 years 
schooling  
HR 0.23 (0.05–0.98) 
p=0.016 
n y y 
Betterman1
06 
Recruited from 4 USA 
academic centres 
6  482 All Deme
ntia 
(expe
rt 
panel
) 
age, sex, race, 
APOE, 
education, 
stroke, HD 
CPH Statin ever HR 0.88 (0.64-1.21) 
p=.43 
n y y 
Other lipid lowerer  HR 0.78 (0.36-1.68), 
p= .52 
Brodaty42 9 Australian memory clinics 3 185 All (P) Deme
ntia  
Age, sex, MMSE CPH Depression (NPI 
subscale) 
HR 1.08 (0.98-1.19)    
NPI (total & 6 m 
change) 
Not significant, results 
not given 
Chilovi et 
al58 
Outpatient aging clinic, 
Brescia, Italy 
2  
 
124 All 
S/ICC 
Deme
ntia 
Age, Barthel 
Index, ADAS-
Cog 
LR Clinical depression OR 0.10 (0.02–0.39); 
p=0.001 
n y y 
Clinically significant 
apathy 
OR 7.07 (1.99–25.17); 
p=0.003 
Devanand 
67 
 4.
5  
13
9 
All 
SMC 
Dem
entia 
- **UC Education (years) C/NC: mean 14.1(SD 
4.5) vs 15.6 (4.0) 
n y y 
Devier 53 New York Memory clinic 
attendees, without 
psychiatric diagnosis  or 
CVA 
1-9  108 
148 
aMCI 
All ; 
SMC 
AD Cognition, 
education and 
stratified for age 
(and other 
variables tested) 
CPH State anxiety HR 1.68 (0.75- 3.77) 
p=0.21 
n y y 
Trait anxiety aMCI: 0.35 (0.14- 0.85) 
p=0.02 
All MCI: HR 0.36 
(0.16- 0.82) p=0.015 
Hamilton depression 
score 
All MCI: HR 1.01 (0.92- 
1.10) p=0.86 
aMCI NS (results not 
given) 
Education (years) HR 1.01 (0.93, 1.10) 
p=0.81 
   
Edwards 49 Records, Californian memory 
clinics 
1.6  270 All Deme
ntia  
Age, MMSE, 
function, site, 
comorbidity 
LR 4+ neuropsychiatric 
symptoms 
OR=2.44 (1.07–5.55) n n y 
30 
 
Farias 74 Clinic referrals and outreach  2 111
1 
All Deme
ntia 
memory, age, 
education 
CPH Education (years) NS n y y 
Fellows 38 Canadian memory clinic 3.3  
 
90 aMCI 
S/IMC 
AD 
 
age onset, 
MMSE, sex, 
education, 
function 
UC; LR Smoking (pack years) OR 0.98 (0.95-1.00) 
p=0.13 
n y y 
      None **UC Education (years) C/NC: (mean(SD): 
10.6 (3.6) vs 10.9 
(3.3)  
n y y 
GeDS >6 C/NC 55 vs 62, 
p=0.53 
Alcohol consumption C/NC 45 vs 44, 
p=0.92 
Vascular risk factors  C/NC 60 vs 45 p=0.15 
Fleischer 
107 
Participants in an RCT  3  539 aMCI AD  Age, sex, 
cognition, FHx  
GLM Education (years) NS n y y 
Gabryele
wicz  52 
Participants in a longitudinal 
study recruited from 
consecutive referrals to 
Warsaw clinic MADRS 
score 28 or less 
3 10
5 
All 
SMC 
Dem
entia 
 
Age ANC
OVA 
Higher baseline 
MADRS score 
F=4.83, p=0.010 n y n 
Gavrilova 
64 
Higher baseline 
homocysteine 
levels 
MD-MCI: 16.53 
umol/l vs 14.36 
umol/l; U=713, 
P=0.037 aMCI: ns 
Grande82 Milan (Italy) memory clinic Me
dia
n 
2.6 
176 All 
SCC 
Deme
ntia  
age, gender, 
education, 
MMSE, GDS, 
MCI subtype, 
APOE  
CPH Physical activity score 
(vs lowest tertile): 
middle 3le 
HR 0.59 (0.32 to 1.10) n y y 
Highest tertile HR 0.36 (0.18 to 0.75) 
Social activity score 
(vs lowest tertile): 
middle 3le 
HR 0.82 (0.54 to 2.15) 
Highest tertile HR 0.42 (0.68 to 2.56) 
Cognitive activity 
score (vs lowest 
tertile): middle 3le 
HR 0.54 (0.26 to 1.14) 
Highest tertile HR 0.89 (0.45 to 1.77) 
31 
 
Ravaglia 27 
 
Bologna (Italy) geriatric clinic 
attendees aged 60+ with 
reliable informant, without 
psychiatric disorder recruited 
from March 1999 to March 
2004 and August 2005 (Forti 
Me
an 
2.8  
 
165 All 
S/IMC 
MMSE 
>23 
Deme
ntia, 
deficit
s in 
2+ 
cognit
ive 
doma
ins 
affecti
ng 
functi
oning 
Age, gender, 
education 
CPH Ever smoking HR 0.54 (0.22–1.32) 
p<0.177 
n y y 
Diastolic bp (-
10mmHg) 
HR 0.56 (0.39–0.80) 
p<0.001 
Systolic (-10mmHg) HR 0.81 (0.69–0.95) 
p<0.013 
Hypertension HR 1.25 (0.70–2.45) 
p<0.453 
BMI (vs 25.1-27.6): 
<25 
HR 2.07 (1.04–4.14) 
p<0.039 
27.7–29.9 HR 0.53 (0.20–1.37) 
p=0.189 
>30 HR 0.62 (0.26–1.46) 
p=0.270 
Diabetes HR 0.75 (0.26–2.13) 
p<0.593 
Cardiovascular 
disease 
HR 0.90 (0.44–1.84) 
p<0.780 
Chol (Ref  5.3–6.):  
<5.3: 
HR 1.78 (0.85–3.70) 
p=0.123 
6.0-6.5 mmol/l HR 0.38 (0.13–1.07) 
p=0.068 
>6.5 mmol/l HR 0.29 (0.09–0.87) 
p=0.028 
Vitamin B12 ≤217 
pmol/l  
HR 0.60 (0.26–1.39) 
p=0.234 
Serum folate ≤ 10.4 
nmol/l 
HR 2.23 (1.12–4.43) 
p=0.022 
Forti 83 180 + MMSE, bp, 
BMI, folate 
CPH Atrial fibrillation HR 4.63 (1.72-12.46) 
p<0.002 
n y y 
    None **UC Education >5 years C/NC: 14 (26.9) vs 
29(22.6) p=0.54 
n y y 
32 
 
Maioli 34 1.
2 
52   None **UC Serum HDL mg/dl C/NC 70(25) vs 58 
(13), p=0.058 
n y y 
 Serum LDL mg/dl C/NC: 106 (42) vs 122 
(52) p=0.359 
Hansson 32 Attendees from a Swedish 
memory clinic, who agreed 
to provide a sample of CSF 
4  137 aMCI 
SMC 
AD  
 
age, sex, 
education level, 
APOE ɛ4  
CPH Received higher 
education 
HR 0·80 (0·45–1·43) n y y 
Systolic bp HR 1·00 (0·98–1·01) 
Diastolic bp HR 0·99 (0·97–1·02) 
Homocysteine HR 1·08 (1·04–1·12) 
Hsiung 
43;108 
 2  68 All; 
MCI 
on 
exam 
AD, 
VaD  
age, sex LR Education (years) AD: OR 0.82 (.76–.89) 
VaD: 0.62 (.49–.79)  
n n y 
 Recruited from 8 Canadian 
memory clinics 
     **UC NPI C/NC: 4.3(6.3) vs 11.0 
(20.1) 
n n y 
Chronic medical 
illness 
C/NC 5.2 (4.3) vs 5.3 
(3.9) 
Jack 28 Consecutive patients 60-89 
from Mayo clinic research 
registry 
2.
7 
 
80 S/IMC 
aMCI 
AD 
 
none nonpa
ramet
ric 
CPH 
Hypertension  RR 1.63 p=0.272 n y y 
Ischemic heart 
disease  
RR 0.55 p=0.272 
Estrogen 
replacement  
RR 1.09 p=0.864 
Korf 31 Consecutive attenders at a 
geriatric clinic, Stockholm, 
Sweden 
2.
8 
 
75 All Dem
entia 
time CPH Education (years) HR 0.93 (0.82–1.06) n y y 
Hypertension HR 0.62 (0.27–1.42) 
Depression HR 0.76 (0.38–1.52) 
Lee 81 Aged 55+, ≥1 FU, South 
Korean study  
1.4
7  
504 All; 
SCC 
AD Age, MMSE 
score 
CPH Education (years) HR 1.08 (1.04–1.13) 
p<0.001 
n y y 
Li 19 Inpatients in a Chinese 
hospital those with CVA or 
depressive disorder 
excluded 
3  
 
257 aMCI 
SMC 
AD  Age, covariates 
listed; carotid 
stenosis, stroke 
during follow-up 
and white matter 
changes 
CPH diabetes mellitus  HR 2.39 (1.07–5.33) 
p=0.03 
n y y 
Education (> 6 years) HR 0.48 (0.21–1.10) 
p=0.08 
Hypertension HR 0.71 (0.22–2.22) 
p=0.55 
33 
 
Antihypertensives HR 1.22 (0.48–3.13) 
0.68 
antihyperglycemic  HR 2.08 (0.66–6.54) 
p=0.21 
Luis 109 Record review Miami 
memory clinic  
2.4  134 All 
SCC 
Deme
ntia 
Age, sex, MMSE, 
subtype 
CPH Education (years) NS (results not given) n y y 
Mauri 110 Italian outpatient clinic 
patients  
3  
 
11
9 
All Dem
entia 
None No 
tests 
Mild parkinsonism 
symptoms at 
baseline 
11/22 (50%) with 
MPS at baseline and 
35/97 without 
developed dementia; 
trend (p<0.05) for 
vascular dementia 
n y y 
Modrego 
51 
Consecutive Spanish 
outpatient clinic patients 
3  
 
11
4 
aMCI 
SMC 
Dem
entia 
None Log 
rank 
test 
Depression 
diagnosed by 
structured clinical 
interview 
HR: 4.1; 2.4-6.9 n y y 
Olazaran 
77 
Recruited by primary care 
physicians in a Madrid 
practice 
1  
 
81 All Dem
entia 
Age, sex LR Higher educational 
level (not illiterate 
or incomplete 
education) 
OR 0.13 (0.02–0.77) 
0.024 
n y y 
Palmer56 Consecutive new diagnoses 
at 3 Rome memory clinics  
4  
 
131 aMCI AD  age, sex, apathy, 
MMSE, 
education, 
depression 
CPH Depression diagnosis HR 0.6 (0.2–1.8) n y y 
Apathy diagnosis HR 6.9 (2.3–20.6) 
NPI apathy score 2+ HR=4.6 (1.3−16.2)    
Peavy 111 Research centre & clinic, 
aged 65+, no mental illness, 
3 follow-ups 
2.5  33 All (P) Deme
ntia 
Age, gender, 
education, 
cortisol, APOE 
LR Education (years) NS (data not shown) n y y 
Perri 112 Aged 50-80, USA memory 
clinics, ≥5 years education 
2  190 aMCI 
S+IMC 
AD 
 
Age, gender, 
cognition 
LR Education (years) NS (p=0.85) n y y 
Prasad 20 Patients at a tertiary 
neurology memory clinic  
with follow-up information 
1.
5  
79 aMCI 
Peters
en 
criteria 
Dem
entia 
(all 
AD) 
none **UC Education (years) C/NC: 8.3 vs10.2 p = 
0.098 
n n y 
Diabetes mellitus C/NC: n=10 (43.5%) 
vs 15 (28.9) p=0.215 
34 
 
available for 18 months 
including MRI scans 
Hypertension  C/NC: 11 (47.8) vs 28 
(52.8) p=0.094 
Hyperlipidemia  C/NC: 10 (45.4) vs 36 
(67.9) p=0.032 
Mackin 35 ADNI database, recruited 
from 50+ sites in USA and 
Canada without depression 
(GDS<6) 
2-3 405 aMCI 
S+IMC 
MMSE 
>23 
 
AD ApoE, 
intracranial 
volume, white 
matter lesions, 
demographics 
removed as NS 
CPH GDS score 1-5 (sub 
syndromal 
depression) vs 
GDS=0 
NS (statistics not 
given) 
n y y 
 3  
 
22
7 
SMC 
aMCI 
Dem
entia 
(NIN
CDS
) 
None **UC Education (years) C/NC: 15.9 (2.9) vs 
16.0 (2.8) p=0.72 
n n y 
GeDS 6+ at follow-
up 
OR = 1.88, p = 0.15 
GeDS score C/NC: 1.6 (1.3)  vs 1.5 
(1.4)  p=0.38 
Serum LDL mg/dl C/NC:106 (42) vs 122 
(52) p=0.359 
Morris21 2 264 Education, age, 
sex 
ANOV
A 
Impaired glycaemia C/NC:48.5% vs 32.3% 
p=0.009 
n y y 
Richard 55 me
an 
2.7  
 
151 age, gender, 
education and 
baseline MMSE 
score 
CPH Apathy symptoms  HR 1.85 (1.09–3.15) n y y 
219 CES-D score 4+  HR 1.15 (0.72–1.83) 
211 Apathy and 
depression  
HR 1.05 (0.91–1.23) 
Schneider 
84 
2  402 age, APOE, 
education  
ADAS-cog score 
Weibull 
R 
ChEI  vs no 
treatment 
29.8% reduced time 
to dementia (P=.005) 
n y y 
ChEI and 
memantine  
41.8% reduced time 
to dementia (P=.003) 
Robert 57 Patients from 14 French 
memory clinics aged 58+, >4 
years education, with 
informant; not MADRS 
score >20 or significant brain 
vascular change  
1  216 aMCI 
SMC 
MMSE  
>24 
AD  age, sex, 
educational level, 
MADRS total 
score and 
Goldberg anxiety 
scale 
LR Psychiatric history  C/NC 31.8 vs 19.7, 
p=0.16 
n y y 
Education (% tertiary)  C/NC 31.8  vs 44.3, 
p=0.22 
Goldberg anxiety 
scale  
C/NC 2.6 (2.5) vs 2.9 
(2.5) p=0.16 
35 
 
MADRS total score 
(% >10)  
C/NC 31.8 vs 18.6, 
p=0.26 
Apathy  C/NC 59.1 vs 37.6, 
p=0.10 
Rosenberg 
50 
Data from National 
Alzheimer Coordinating 
Center database, USA 
Me
dia
n 
1.5
8  
182
1 
All 
Expert 
diagno
sis 
Deme
ntia 
AD  
Cognition, age, 
ethnicity 
CPH NPI middle vs 
lowest tertile 
Dementia/AD: HR 
1.43 (1.15–1.80) 
p=0.002/ 1.48 (1.17–
1.88) p=0.001 
   
n n y 
NPI top vs lowest 
tertile 
HR 1.5(1.2–
1.9)<.001/1.4(1.1–
1.7) .013 
GDS mid vs lowest 
tertile 
HR 1.4 (1.1–1.7)  .003 
/ 1.3 (1.0–1.6) p=0.05 
GDS top vs lowest 
tertile 
HR 1.37 (1.1–1.71) 
p=0.01/1.17 (.92–
1.5)p=.21 
Rozzini 
113 
Consecutive referrals to 
Italian memory clinic 
2  46 Not 
stated 
Dem
entia 
None **UC Depression 
diagnosis at 
baseline 
17/24 without 
depression developed 
dementia vs 8/22 with 
depression 
n y y 
Rozzini 44 1  11
9 
aMCI 
S/IMC 
AD None **UC Education (years) NS n y y 
NPI C/NC: 14.5 (11.2) vs  
12.6 (10.7) NS 
GeDS C/NC: 4.3 (3.6) vs 4.7 
(3.1) NS 
Hamilton anxiety 
scale 
C/NC: 8.5 (6.4) vs 
10.4 (6.5) 
Number of drugs C/NC: 2.8 (2.2) vs 2.5 
(1.8) 
Sachdev 
79 
Patients at two Australian 
hospitals , 3-6 months after 
ischaemic stroke / TIA 
3  45 All Vasc
ular 
dem
entia 
None **UC Education (years) NS (stats not given) n n y 
36 
 
Siuda 63 Polish Neurology outpatient 
clinic 
1  55 SMC 
Objecti
ve 
cogniti
ve imp 
Dem
entia 
None **UC Total homocysteine 
(μmol/L) 
C/NC: 19.83 (7.31) vs 
19.85 (7.64) p=0.645 
n y y 
Vitamin B12 (pg/mL) C/NC: 376.11 
(173.44) vs  495.32 
(335.78) p=0.143 
   
Folic acid (ng/mL) C/NC: 3.60 (1.72) vs 
3.75 (1.90) p=0.752 
   
Squitti65 Italian memory clinic, GDS 
<14 
2-6 141 aMCI AD Age, gender, 
MMSE 
CPH Serum 
Nonceruloplasmin 
Copper 
HR 1.23 (1.03–1.47), 
p=0.022 
n y y 
transferrin, ferritin 
hypercholesterolemia, 
hypertension 
Not significant (data 
not shown) 
Taragano 
48 
Consecutive patients, 
Argentinian clinic 
5  23
9 
Any 
SCC 
Dem
entia 
None stated CPH Psychiatric 
symptoms 
HR 4.01 (2.5-6.3) n y y 
Teng 46 Memory clinic patients aged 
50+  
2  51 Any 
SCC 
AD MMSE, subtype, 
sex  
ANC
OVA 
Any 
neuropsychiatric 
symptoms  
F(1, 40) = 5.23 
p=.028 
n y y 
Velayudha
n 23 
People aged 65+ primary 
care practices in south 
London, UK 
4  61 aMCI 
SMC  
Deme
ntia 
 
Age, gender, 
APOE, IQ, 
education, 
smoking, health  
CPH Diabetes HR 2.9 ( 1.1–7.3) n y y 
Duration of diabetes HR 0.9 (0.7–1.1) 0.29 
      None   Depression HR 1.4 (0.5–3.9) 
p=0.5 
n y y 
Education  HR 1.0 (0.9–1.2) 
p=0.61 
Coronary heart 
disease  
HR 1.1 (0.4–2.8) 
p=0.85 
Drinking alcohol  HR 2.6 (0.7–8.8) p-0.1 
Lifetime smoking 
status  
HR 0.8 (0.17–4.3) 
p=0.8 
Visser 114 10  64 SMC 
aMCI 
Dem
entia 
- **UC Education (years) chi2<1.4, p >0.23 n y y 
37 
 
Visser 54 new consecutive patients, 
Maastricht memory clinic  
without vascular MCI 
5  74 SMC 
aMCI 
Dem
entia 
(All 
AD) 
- **UC Education (years) C/NC: 10.3 (3.6) vs 
11.2(2.6) NS 
n y y 
Depression 
(baseline) 
C/NC: 26% vs 50%, 
NS 
Depression (follow-
up) 
C/NC: 7% vs 29% NS 
Xu 40 Male patients from 2 
Chinese neurology 
outpatient clinics 
2  16
3 
SMC 
any 
Dem
entia 
- KM Heavy vs light to 
moderate alcohol 
use 
P<0.05 n y y 
Heavy drinkers vs 
abstainers 
P<0.05 
Yasar33 Participants with MCI in USA 
RCT of Ginkgo Biloba 
6.1 320 All AD age, sex, 
education, 
income, no. of 
vascular 
diseases, BMI 
CPH Diuretic vs no 
antihypertensive 
use 
HR 0.38 (0.20–0.73) 
0.004 
n y y 
Other cardiovascular 
drugs 
Not significant 
predictors 
Ye 71 Consecutive patients in 31 
South Korea memory clinics  
Me
an 
1.4
3  
249 aMCI 
SMC 
AD age, gender, and 
baseline MMSE  
CPH Education (>8 
years) 
HR 2.18 (1.10–4.32); 
Late-stage: 2.38; p 
=0.03  Early: NS 
n y y 
Ye 66 People in National USA 
MRI study  
4  31
9 
aMCI 
SMC 
Prob
able 
AD 
- **UC Education (years) C/NC: 15.77 ± 2.90 vs 
15.65 ± 3.06,  p=0.7 
n y y 
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